Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Jun;87(2):417-42.
doi: 10.1111/j.1468-0009.2009.00563.x.

The Converged Experience of Risk and Disease

Affiliations
Free PMC article
Review

The Converged Experience of Risk and Disease

Robert A Aronowitz. Milbank Q. .
Free PMC article

Abstract

Context: One underappreciated consequence of modern clinical and public health practices is that the experience of being at risk for disease has been converging with the experience of disease itself. This is especially true for certain chronic diseases, in which early diagnosis and aggressive treatment have led to symptom-less and sign-less disease and in which treatments have largely been aimed at altering the disease's future course.

Methods: This article reviews the historical scholarship and medical literature pertinent to transformations in the chronic disease and risk experiences.

Findings: The experience of chronic disease increasingly resembles or has become indistinguishable from risk because of (1) new clinical interventions that have directly changed the natural history of disease; (2) increased biological, clinical, and epidemiological knowledge about the risk of chronic disease; (3) the recruitment of larger numbers into chronic disease diagnoses via new screening and diagnostic technology and disease definitions; (4) new ways of conceptualizing efficacy; and (5) intense diagnostic testing and medical interventions.

Conclusions: The converged experience of risk and disease has led to some unsettling and generally underappreciated consequences that might be subjected to more clinical and policy reflection and response: (1) some puzzling trends in medical decision making, such as the steep and uniform increase in the numbers of women across a broad spectrum of risk/disease in breast cancer who have opted for prophylactic mastectomies; (2) a larger and highly mobilized disease/risk population, resulting in an expanded market for interventions and greater clout for disease advocates; (3) shifts in the perceived severity of the disease, with ripple effects on how people experience and understand their illness and risk of disease; and (4) interventions that promise both to reduce the risk of disease and to treat its symptoms.

Figures

Figure 1
Figure 1
Trends in the Proportion of All Surgically Treated Patients Who Underwent Contralateral Prophylactic Mastectomy (CPM-A) by Cancer Stage at Diagnosis Note: The Cochran-Armitage tests for trend for CPM-A rates overall and by stage were significant (p < .001). Source: T.M. Tuttle, E.B. Habermann, E.H. Grund, T.J. Morris, and B.A. Virnig, Increasing Use of Contralateral Prophylactic Mastectomy for Breast Cancer Patients: A Trend toward More Aggressive Surgical Treatment, Journal of Clinical Oncology (published online, October 22, 2007). Reproduced with permission of the Journal of Clinical Oncology.

Similar articles

See all similar articles

Cited by 20 articles

See all "Cited by" articles

Publication types

MeSH terms

Feedback